Mexico’s Cofepris has established an abbreviated registration pathway recognising ANVISA evaluations, with a 45-business-day resolution ceiling — accelerating market entry for manufacturers already cleared in Brazil.
Mexico’s Cofepris has established an abbreviated registration pathway recognising ANVISA evaluations, with a 45-business-day resolution ceiling — accelerating market entry for manufacturers already cleared in Brazil.
Mexico’s IMSS and Health Ministry have agreed to make electronic clinical records interoperable across public institutions, with inter-institutional data exchange scheduled to begin in January 2027 under the Universal Health …
Brazil’s securities regulator has ordered a tender offer for Oncoclínicas shares, with analysts estimating the total outlay at R$ 12–14 billion — roughly double initial projections — as a parallel …
Ecuador’s Sercop signed 114 medication supply agreements in May–June 2026, but 71 carry no purchase orders as of mid-August — leaving contracted suppliers unpaid and public hospital shelves empty.
Brazil’s Conselho Federal de Medicina activated Resolution 2.454/2026 on August 26, imposing immediate ethical sanctions on physicians and institutions deploying AI without governance frameworks.
Clinics across four Patagonian provinces suspended all PAMI patient care for 24 hours, citing a 143% tariff adjustment against 341% cumulative inflation — a gap that may signal broader provider …
Brazilian startup PoliHealth is integrating genetic, laboratory, and lifestyle data into a single AI platform for clinicians, targeting R$8 million in revenue and 30,000 health professional users within three years.
Anvisa cancelled Elevidys’s conditional registration on August 24 at Roche’s request, citing insufficient safety and efficacy data — ending Brazilian access to the country’s most expensive approved drug.
The FDA has approved Revolution Medicines’ daraxonrasib (Rasonque) for metastatic pancreatic adenocarcinoma, after a phase III trial of 500 patients showed median overall survival of 13.2 months versus 6.7 months …
Anvisa has approved datopotamab deruxtecan (Datroway) for adults with advanced EGFR-mutated non-small cell lung cancer in Brazil, expanding targeted therapy options in one of oncology’s most active segments.
You must be logged in to post a comment.